Name: Mirtazapine
Brand: Selleck Chemicals
SKU: S2016
Availability: InStock
Rating: 5 (1 reviews)

Jump to

Quality Control

Batch: S201601 DMSO]53 mg/mL]false]Ethanol]53 mg/mL]false]Water]Insoluble]false Purity: 99.99%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS/MSDS
Datasheet

99.99

Related Targets	Adrenergic Receptor AChR COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other 5-HT Receptor Inhibitors	Serotonin Hydrochloride (5-HT HCl) WAY-100635 Maleate Puerarin SB269970 HCl Ketanserin BRL-15572 Dihydrochloride Nuciferine RS-127445 Flopropione Azacyclonol

Solubility

In vitro
Batch:

DMSO : 53 mg/mL (199.73 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 53 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.65mg/ml (9.99mM)	Taking the 1 mL working solution as an example, add 50 μL of 53 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.37mg/ml (1.39mM)	Taking the 1 mL working solution as an example, add 50 μL of 7.4 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	265.35	Formula	C₁₇H₁₉N₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	85650-52-8	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Org3770,6-Azamianserin			SMILES	CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	5-HT
In vitro	Mirtazapine displays marked affinity for cloned, human alpha2A-adrenergic (AR) receptors at which it blocks noradrenaline (NA)-induced stimulation of guanosine-5'-O-(3-[³⁵S]thio)-triphosphate ([³⁵S]-GTPgammaS) binding. This compound shows high affinity for cloned, human serotonin (5-HT)2C receptors at which it abolishes 5-HT-induced phosphoinositide generation. It markedly elevates dialysate levels of NA and, in FCX, DA, whereas 5-HT is not affected. This chemical enhances the effectiveness of the electrical stimulation of the ascending 5-HT pathway by blocking both alpha-2 adrenergic auto- and heteroreceptors. It blocks the suppressant effect of microiontophoretically applied norepinephrine (NE) on the firing activity of CA3 dorsal hippocampus pyramidal neurons, indicating their antagonistic effects on postsynaptic alpha-2 adrenoceptors.
In vivo	Mirtazapine (10-250 mg/kg i.v.) enhances dose-dependently the firing activity of the 5-HT neurons in naive rats, but not in 6-hydroxydopamine-pretreated rats. This compound (5 mg/kg/day, s.c., using osmotic minipumps) increases the spontaneous firing activity of locus coeruleus noradrenaline (NA) neurons in male Sprague-Dawley rats. It antagonizes both the enhancing effect of a low dose (10 mg/kg, i.v.) and the reducing effect of a high dose (100 mg/kg, i.v.) of the alpha 2-adrenoceptor agonist clonidine on the effectiveness of the electrical stimulation of the ascending 5-HT pathway in suppressing the firing activity of dorsal hippocampus CA3 pyramidal neurons. This chemical (5 mg/kg s.c.) only slightly affects DOPAC and homovanillic acid levels in the striatum, hardly affects 5-HT release in freely moving rats, but clearly increased 5-hydroxyindole acetic acid.
References	[1] https://pubmed.ncbi.nlm.nih.gov/10762339/ [2] https://pubmed.ncbi.nlm.nih.gov/15102749/ [3] https://pubmed.ncbi.nlm.nih.gov/9007838/ [4] https://pubmed.ncbi.nlm.nih.gov/8627567/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-09-24)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03935685	ACTIVE_NOT_RECRUITING	Glioma of Brain	University of California, Irvine	2019-02-26	PHASE2
NCT00488072	ACTIVE_NOT_RECRUITING	Advanced Cancer; Anorexia; Weight Loss; Insomnia	M.D. Anderson Cancer Center	2007-01-08	PHASE2
NCT06684470	RECRUITING	IBS - Irritable Bowel Syndrome; Diarrhea	Mayo Clinic	2024-12-19	EARLY_PHASE1
NCT06323837	RECRUITING	Stimulant Use Disorder	Washington State University	2024-06-17	PHASE2
NCT05170919	ENROLLING_BY_INVITATION	Anorexia Nervosa with Significantly Low Body Weight	Englewood Hospital and Medical Center	2022-01-20	PHASE2
NCT07430046	RECRUITING	RETT Syndrome With Proven MECP2 Mutation	University of Trieste	2025-07-09	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Mirtazapine 5-HT Receptor antagonist

Chemical Structure

Molecular Weight: 265.35